October 29, 2018 10:14 AM EDT

Out to challenge Gilead's daily pills, Viiv scores three-year data on monthly combo; Rigel bags $33M from Asia licensing deal

Amber Tong

→ On the heels of an NDA submission, Viiv has posted longterm data supporting its theory that another one of its long-acting two-drug combos could …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Out to challenge Gilead's daily pills, Viiv scores three-year data on monthly combo; Rigel bags $33M from Asia licensing deal

Amber Tong

Sign up to read this article for free.

Updated: Amgen obesity shot shows 20% weight loss, but dosing questions hang over readout

Sarepta licenses Arrowhead's RNA-based rare disease pipeline, promising big biobucks

Updated: Roche buys out CAR-T partner Poseida for $1B upfront

Alector says Alzheimer's program targeting microglia fails Phase 2, stock dives

Roche’s TIGIT drug misses last shot at survival endpoint win in Phase 3 lung cancer trial

Food allergy biotech Alladapt closes after Phase 3 talks with FDA

Out to chal­lenge Gilead­'s dai­ly pills, Vi­iv scores three-year da­ta on month­ly com­bo; Rigel bags $33M from Asia li­cens­ing deal

Amber Tong

Sign up to read this article for free.

more like this

Up­dat­ed: Am­gen obe­si­ty shot shows 20% weight loss, but dos­ing ques­tions hang over read­out

Sarep­ta li­cens­es Ar­row­head­'s RNA-based rare dis­ease pipeline, promis­ing big biobucks

Up­dat­ed: Roche buys out CAR-T part­ner Po­sei­da for $1B up­front

Alec­tor says Alzheimer's pro­gram tar­get­ing mi­croglia fails Phase 2, stock dives

Roche’s TIG­IT drug miss­es last shot at sur­vival end­point win in Phase 3 lung can­cer tri­al

Food al­ler­gy biotech Al­ladapt clos­es af­ter Phase 3 talks with FDA

Out to challenge Gilead's daily pills, Viiv scores three-year data on monthly combo; Rigel bags $33M from Asia licensing deal

Updated: Amgen obesity shot shows 20% weight loss, but dosing questions hang over readout

Sarepta licenses Arrowhead's RNA-based rare disease pipeline, promising big biobucks

Updated: Roche buys out CAR-T partner Poseida for $1B upfront

Alector says Alzheimer's program targeting microglia fails Phase 2, stock dives

Roche’s TIGIT drug misses last shot at survival endpoint win in Phase 3 lung cancer trial

Food allergy biotech Alladapt closes after Phase 3 talks with FDA